244 results match your criteria: "Royal Brompton Hospital and Imperial College[Affiliation]"
Climacteric
October 2024
National Heart and Lung Institute, Royal Brompton Hospital and Imperial College London, London, UK.
Objective: Oral, low-dose and ultra-low-dose continuous combined 17β-estradiol (E) plus dydrogesterone (D) reduce vasomotor symptoms (VMS) in postmenopausal women.
Methods: Two phase 3, double-blind studies were included. In the European study, postmenopausal women were randomized 2:1:2 to receive E0.
Gynecol Endocrinol
December 2024
Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Am J Respir Crit Care Med
August 2024
Royal Brompton Hospital and Imperial College, London, United Kingdom.
J Cyst Fibros
May 2024
IRCCS Istituto Giannina Gaslini, Cystic Fibrosis Center, Genoa, Italy.
After three publications defining an updated guidance on the diagnostic criteria for people with cystic fibrosis transmembrane conductance regulator (CFTR)-related disorders (pwCFTR-RDs), establishing its relationship to CFTR-dysfunction and describing the individual disorders, this fourth and last paper in the series addresses some critical challenges facing health care providers and pwCFTR-RD. Topics included are: 1) benefits and obstacles to collect data from pwCFTR-RD are discussed, together with the opportunity to integrate them into established CF-registries; 2) the potential of infants designated CRMS/CFSPID to develop a CFTR-RD and how to communicate this information; 3) a description of the challenges in genetic counseling, with particular regard to phenotypic variability, unknown long-term evolution, CFTR testing and pregnancy termination 4) a proposal for the assessment of potential barriers to the implementation and dissemination of the produced documents to health care professionals involved in the care of pwCFTR-RD and a process to monitor the implementation of the CFTR-RD recommendations; 5) clinical trials investigating the efficacy of CFTR modulators in CFTR-RD and how endpoints and outcomes might be adapted to the heterogeneity of these disorders.
View Article and Find Full Text PDFChest
February 2024
Department of Pulmonology, Morgagni-Pierantoni Hospital, Forlì, Italy.
CJC Pediatr Congenit Heart Dis
December 2023
Toronto ACHD Program, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
J Cyst Fibros
January 2024
Adult Cystic Fibrosis Centre, Royal Brompton Hospital and Imperial College, London, UK.
Int J Cardiovasc Imaging
March 2024
Department of Cardiology, Northwick Park Hospital, Harrow, UK.
Purpose: The efficacy and safety of ultrasound enhancing agent (UEA) was unknown in the COVID-19 hospitalized patients. We set out to establish the utility of UEA and its safety profile.
Methods: A retrospective observational study of prospectively assessed hospitalized patients referred for transthoracic echocardiography (TTE) for suspected cardiac pathology due to COVID-19.
Echo Res Pract
November 2023
Liverpool Centre for Cardiovascular Science, Liverpool John Moores University, Liverpool, UK.
Ultrasound contrast agents (UCAs) have a well-established role in clinical cardiology. Contrast echocardiography has evolved into a routine technique through the establishment of contrast protocols, an excellent safety profile, and clinical guidelines which highlight the incremental prognostic utility of contrast enhanced echocardiography. This document aims to provide practical guidance on the safe and effective use of contrast; reviews the role of individual staff groups; and training requirements to facilitate its routine use in the echocardiography laboratory.
View Article and Find Full Text PDFJ Cyst Fibros
November 2023
Department of Women's and Children's Health, University of Liverpool, Liverpool, UK. Electronic address:
Lancet Respir Med
January 2024
Department of Pediatrics, Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Background: Mucociliary clearance is dysfunctional in people with primary ciliary dyskinesia, resulting in the accumulation of dehydrated mucus in the airways that is difficult to clear. We undertook a study to assess the benefit on lung function of treatment with a nebulised epithelial sodium channel (ENaC) blocker, idrevloride, with or without hypertonic saline, in people with primary ciliary dyskinesia.
Methods: The CLEAN-PCD trial was a phase 2, randomised, double-blind, placebo-controlled crossover trial conducted at 32 tertiary adult and paediatric care centres and university hospitals in Canada, Denmark, Germany, Italy, the Netherlands, Poland, the UK, and the USA.
Thorax
November 2023
Academic Respiratory Unit, University of Brisol and North Bristol NHS Trust, UK.
J Cyst Fibros
January 2024
Coordinator ECFS NSWG, Paediatric Pulmonology & CF Centre, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
Nature
July 2023
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
The function of a cell is defined by its intrinsic characteristics and its niche: the tissue microenvironment in which it dwells. Here we combine single-cell and spatial transcriptomics data to discover cellular niches within eight regions of the human heart. We map cells to microanatomical locations and integrate knowledge-based and unsupervised structural annotations.
View Article and Find Full Text PDFThorax
July 2023
Academic Respiratory Unit, University of Bristol and North Bristol NHS Trust, Bristol, UK.
Curr Opin Pulm Med
September 2023
Royal Brompton Hospital and Imperial College, London, UK.
Purpose Of Review: To characterize patterns of disease progression in the designation of progressive pulmonary fibrosis (PPF), including their relative prevalence and subsequent prognostic significance, in patients with fibrotic interstitial lung disease (ILD), including key patient sub-groups.
Recent Findings: In recent large clinical cohorts, PPF criteria suited to early PPF identification, based on their prevalence and short time to progression, include a relative forced vital capacity (FVC) decline exceeding 10% and various combinations of lower thresholds for FVC decline, symptomatic worsening and serial progression of fibrosis on imaging. Amongst numerous candidate PPF criteria, these progression patterns may have the greatest prognostic significance based on subsequent mortality, although there are conflicting data based on subsequent FVC progression.
Eur J Cardiothorac Surg
October 2023
Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia.
Lancet Respir Med
February 2023
Royal Brompton Hospital and Imperial College, London, United Kingdom.
Usual interstitial pneumonia (UIP) is characterised by a distinctive morphological and radiological appearance that was considered the pathognomonic hallmark of idiopathic pulmonary fibrosis (IPF). However, this peculiar lung remodelling pattern is also seen in other fibrotic interstitial lung diseases, including hypersensitivity pneumonitis, and connective tissue diseases. In this Personal View, we advocate the designation of a UIP pattern as a single, discrete diagnostic entity, amalgamating its primary form and secondary processes in disorders such as hypersensitivity pneumonitis (hypersensitivity pneumonitis with UIP), rheumatoid arthritis (rheumatoid arthritis with UIP), and others.
View Article and Find Full Text PDFQuant Imaging Med Surg
January 2023
Biomedical Research Unit, Royal Brompton Hospital and Imperial College London, London, UK.
Background: The dorsal striatum, a nucleus in the basal ganglia, plays a key role in the execution of cognitive functions in the human brain. Recent studies have focused on how the dorsal striatum participates in a single cognitive function, whereas the specific roles of the caudate and putamen in performing multiple cognitive functions remain unclear. In this paper we conducted a meta-analysis of the relevant neuroimaging literature to understand the roles of subregions of the dorsal striatum in performing different functions.
View Article and Find Full Text PDFJACC Cardiovasc Imaging
November 2022
Cardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Eur Heart J Acute Cardiovasc Care
November 2022
Department of Cardiology, San Gerardo Hospital, ASST-Monza, Monza, Italy.
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to cancer itself or cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them.
View Article and Find Full Text PDFJ Cyst Fibros
November 2022
Department of Women's and Children's Health, University of Liverpool, Alder Hey Children's Hospital, Liverpool, United Kingdom.
This paper is the first in a series providing updated guidance on the definition, evaluation and management of people with a Cystic Fibrosis Transmembrane conductance Regulator (CFTR)-Related Disorder (CFTR-RD). The need for this update relates to more precise characterisation of CFTR gene variants and improved assessment of CFTR protein dysfunction. The exercise is co-ordinated by the European CF Society Standards of Care Committee and Diagnostic Network Working Group and involves stakeholder engagement.
View Article and Find Full Text PDFESC Heart Fail
December 2022
Emergency Institute for Cardiovascular Diseases "Prof. Dr. C.C. Iliescu" Bucharest; University for Medicine and Pharmacy "Carol Davila" Bucharest, Bucharest, Romania.
The coronavirus 2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF). Several consensus documents describe the appropriate diagnostic algorithm and treatment approach for patients with HF and associated COVID-19 infection. However, few questions about the mechanisms by which COVID can exacerbate HF in patients with high-risk (Stage B) or symptomatic HF (Stage C) remain unanswered.
View Article and Find Full Text PDF